DDInter1668 DDInter1676
Siltuximab is a chimeric (human-mouse) monoclonal immunoglobulin G1-kappa antibody produced in a Chinese hamster ovary (CHO) cell line by recombinant DNA technology. Siltuximab prevents the binding of IL-6 to soluble and membrane-bound IL-6 receptors by forming high affinity complexes with human interleukin-6 (IL-6). Its use is indicated for the treatment of adult patients with multicentric Castleman's disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative. MCD is a rare blood disorder caused by dysregulated IL-6 production, proliferation of lymphocytes, and subsequent enlargement of the lymph nodes. It is administered as a 1 hour intravenous infusion every 3 weeks.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Siltuximab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zinc gluconate
Siltuximab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vitamin E
Siltuximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Diroximel fumarate
Siltuximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Propafenone
Siltuximab {u} may lead to a major life threatening interaction when taken with {v} Etanercept
Siltuximab {u} may lead to a major life threatening interaction when taken with {v} Upadacitinib
Siltuximab may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate
Siltuximab may cause a minor interaction that can limit clinical effects when taken with Vitamin E
Siltuximab may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Siltuximab may cause a moderate interaction that could exacerbate diseases when taken with Propafenone
Siltuximab may lead to a major life threatening interaction when taken with Etanercept
Siltuximab may lead to a major life threatening interaction when taken with Upadacitinib